icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
M-F Yuen1, DJ Kim2, F Weilert3, H L-Y Chan4, J Lalezari5, SG Hwang6, T Nguyen7, S Liaw8, N Brown8, K Klumpp8, L Flores8, G Hartman8, EJ Gane9
 
1Queen Mary Hospital, Univ. of Hong Kong, Hong Kong; 2Hallym University, ChuncheonSacred Heart Hospital, Gangwon-do, Republic of Korea; 3Waikato Hospital, Hamilton, New Zealand; 4Prince of Wales Hospital, Chinese Univ. of Hong Kong, Hong Kong; 5Quest Clinical Research, San Francisco, CA, USA; 6CHA BundangMedical Center, Gyeonggi-do, Republic of Korea; 7Research and Education, Inc., San Diego, CA, USA; 8Novira Therapeutics, Doylestown, PA, USA; 9Auckland Clinical Studies, Auckland, New Zealand

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif